Why is RAPP down?
Down 53% in 3 months while the S&P 500 fell 10%.
- It filed a prospectus for convertible notes of $150.0M on Oct 30, 2026, its newest of 3 offering filings.
−2Long-term trend
Down 53% in 3 months while the S&P 500 fell 10%.
−2Long-term trend
Follow RAPP's trial news. Pro members can get an alert when Rapport Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 25.9% more shares than a year ago |
| Latest filing | 8-K, Nov 4 |
RAPP closed +2.7% that day on 22.4x normal volume.
After its last 4 reports it closed +1.8% on average, higher 3 of 4 times.
About 13 quarters
Director James Healy bought 969,480 shares on Oct 28. 29 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
RAPP is #138 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 138 |
Expected to report Tue Mar 9, before the open (in 108 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.84 a share, from $0.71.
“The increase in R&D expense was primarily driven by operational costs related to clinical development of RAP-219, including the Phase 3 FOS program and completion of the bipolar mania Phase 2 trial, and costs to support the progression of the Company’s overall pipeline.”
RAPP's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase in SG&A was primarily driven by costs associated with the growth of the business, including an increase in headcount and related compensation.”
From its results filing (SEC filing · Nov 4)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | +2.7% | +1.9% | +2.0% |
| Aug 5, 2026 | -1.8% | +0.6% | +15.7% |
| May 7, 2026 | +1.2% | +7.7% | +2.8% |
RSI 37.2, MACD above signal, below both averages. Not scored.
6 insiders bought $1.7M across 7 filings in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: RAPP is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
RAPP scores -2 today, which Breakaway calls Poor. It is #138 of 273 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 53% in 3 months while the S&P 500 fell 10%. Cash lasts about 13 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
RAPP scores -2 today, which Breakaway calls Poor (below zero). That is #138 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind RAPP's -2.
6 insiders bought $1.7M across 7 filings in the last 6 months. No open-market sales on record. The newest is Ramiro Sanchez, Director, who bought $98K on Oct 23. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.